Brief: NextCure Says Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure

17/10/2023 15:04

Oct 17 (Reuters) - NextCure Inc  NXTC.O :
    * PRECLINICAL DATA DEMONSTRATE ANTI-SIGLEC-15 TREATMENT
REDUCED
BONE LOSS AND ENHANCED BONE QUALITY IN MICE WITH
MODERATE-TO-SEVERE OSTEOGENESIS IMPERFECTA (OI)

Source text for Eikon:  ID:nGNX5RwHB4 
Further company coverage:  NXTC.O 

 ((Reuters.Briefs@thomsonreuters.com;))